November 17, 2009
On Saturday, KEI filed comments with the WHO EWG's 2nd web based hearing. Our comments focused on the criteria for new proposals.
WHO website on the EWG
NEWS: The EWG secretariat has released a draft evaluation framework, evaluation criteria and the inventory of financing proposals. The EWG is accepting public comments through the Second Web-based Public Hearing. Deadline: September 5 2009. KEI has offered critical comments on the criteria.
In April 2006, WHO released a report by the Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH Report).
How to reform the WHO?
The World Health Organization just published a report on this week’s second meeting of the WHO Expert Working Group (EWG) on R&D Financing.
The PAHO negotiations on the R&D resolution has produced a new draft, which radically guts the provision on transparency of pharmaceutical industry economics.
The US opposed this language:
“(j) to develop, with input from Member States, a possible standard for disclosure of economic data for drug registered for sale, including disclosures of the costs of R&D, the prices of products, and the annual revenues from the sale of products.”
The US agreed to this language:
Today the executive board of the Pan American Health Organization (PAHO) is considering a proposal to have more transparency of the economics of the pharmaceutical industry. (I have separately blogged about this on the Huffpo). Specifically, an amendment offered to a PAHO EB resolution on research, proposed the following: